Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioAssets Development Corp.

Division of Teva Pharmaceutical Industries Ltd.
www.biodevco.com

Latest From BioAssets Development Corp.

Deals Shaping the Medical Industry (12/2009)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Artificial Discs: Where Do We Go from Here?

Artificial discs are experiencing a cooling trend owing to an expected reduction in CMS reimbursement for both cervical and lumbar disc replacement. Many motion preservation companies are reaching critical regulatory milestones that will likely require a step-up in funding to conduct the large scale clinical studies needed to gain PMA approval. Today, companies in this sector are faced with the troubling task of either scaling back R&D programs to conserve cash or raising additional capital to take the next steps. This article first appeared in the June 2008 issue of In Vivo.
Medical Device

Strength in Spine

Those venture capitalists and other investors who have been suggesting recently that the spinal device market is overheated, overcrowded, and basically over as a prime investment opportunity were few and far between at Windhover's "In Spine and Orthopedics" conference held in Las Vegas in December. The meeting, which is the largest strategic partnering conference for emerging spine and orthopedic companies, found investors and entrepreneurs feeling bullish about the prospects for the spinal device market, as reflected in the panel discussion excerpted here.
Business Strategies Platform Technologies

BioAssets: Convergence as Marketing Play

Most drug and device companies approach convergence as a product development issue--the actual combination in a single product of both device and pharmaceutical attributes. But what if convergence were played out as part of a marketing strategy? That's one of the possibilities being explored by BioAssets, a drug company with a novel approach to the use of TNF inhibitors in spine, who hopes to tap into the strong customer relationships that spine device companies have with surgeons.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Teva Pharmaceutical Industries Ltd.
  • Senior Management
  • Robert Kamen, PhD, CSO
    James Gorman, MD, PhD, Pres., CEP, & CMO
  • Contact Info
  • BioAssets Development Corp.
    Phone: (339) 686-2000
    888 Worcester St.
    Ste. 95
    Wellesley, MA 02482
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register